Cardiovascular platform

In vivo animal model systems for myocardial infarction and cardioprotection by ischemic preconditioning and postconditioning: coronary occlusion and reperfusion-induced infarction, measurement of infarct size with proprietary infarct size measurement system (Infarctsize system, see www.infarctsize.com)
Acute heart failure models induced by acute coronary occlusion or coronary occlusion and reperfusion-induced acute myocardial infarction or cardiotoxic agents
Chronic heart failure models induced by coronary occlusion-induced myocardial infarction, cardiotoxic agents, or salt and volume overload
Arrhythmia models induced by myocardial infarction, ischemia and reperfusion, electric stimulation, pro-arrhythmic agents
Custom designed, combined disease models: e.g. myocardial infarction and stroke with risk factors and co-morbidities such as hyperlipidemia and diabetes
Cardioplegia and organ storage models
Cardiac myocyte assays, including stem-cell based assays, for pre-screening cardioprotective, anti-infarction drugs

Ex vivo isolated heart perfusion systems for myocardial infarction, ischemia and reperfusion, arrhythmias, heat-shock
Systemic inflammatory response syndrome models (e.g. septic shock, multiorgan failure)
In vivo cardiac gene and stem cell therapy for proof-of-concept studies and target validation
Large animal models available for proof-of-concept studies
Platelet aggregation systems to test preventive therapy for myocardial infarction
All models are provided by a wide range of biochemical, bio-analytical, and genomic assays, e.g. assessment of oxidative and nitrosative stress, cell signaling, gene and miRNA expression
Cardiotoxic effects of drugs: effect on severity of heart failure, endogenous cardioprotection, infarct size